<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514511</url>
  </required_header>
  <id_info>
    <org_study_id>LP0145-1315</org_study_id>
    <nct_id>NCT03514511</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the safety and tolerability of LEO&#xD;
      138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.&#xD;
&#xD;
      The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics&#xD;
      following administration of LEO 138559 to healthy subjects and subjects with moderate to&#xD;
      severe atopic dermatitis.&#xD;
&#xD;
      Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen&#xD;
      per subject).&#xD;
&#xD;
      Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose&#xD;
      regimens of LEO 138559 (one dose regimen per subject).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Actual">March 2, 2021</completion_date>
  <primary_completion_date type="Actual">March 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of LEO 138559 - numbers of subjects with adverse events</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of LEO 138559 - number of adverse events</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of LEO 138559 - number of local site reactions</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 1) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 2) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 3) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 4) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 5) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 6) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 7) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 8) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 9) or LEO 138559 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 138559</intervention_name>
    <description>LEO 138559 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 138559 placebo</intervention_name>
    <description>LEO 138559 placebo</description>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For healthy subjects and subjects with atopic dermatitis:&#xD;
&#xD;
          -  Males and females without childbearing potential.&#xD;
&#xD;
          -  Age between 18 and 55, inclusive.&#xD;
&#xD;
          -  Body mass index between 18 and 32 kg/m2, inclusive.&#xD;
&#xD;
          -  Healthy apart from atopic dermatitis for the subjects presenting the disease.&#xD;
&#xD;
        For subjects with atopic dermatitis only:&#xD;
&#xD;
          -  History of atopic dermatitis for more than 6 months.&#xD;
&#xD;
          -  Female subjects with childbearing potential and male subjects with female partners&#xD;
             with childbearing potential using highly effective contraception from start of the&#xD;
             trial and until a period after the last administered dose of trial drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For healthy subjects and subjects with atopic dermatitis:&#xD;
&#xD;
          -  Any significant disease detected prior to enrolment.&#xD;
&#xD;
          -  Subjects who are still participating in a clinical trial or who have participated in a&#xD;
             clinical trial within 3 months prior to enrolment or within 5 times of the half-life&#xD;
             of the experimental therapy, whichever is longer.&#xD;
&#xD;
          -  Skin diseases that may interfere with the diagnosis of atopic dermatitis or assessment&#xD;
             of the treatment.&#xD;
&#xD;
          -  Use of tanning beds or phototherapy within 6 weeks prior to enrolment.&#xD;
&#xD;
          -  Subjects with atopic dermatitis requiring more than 3 bleach baths from 4 weeks prior&#xD;
             to screening until end of trial.&#xD;
&#xD;
          -  Blood pressure or pulse rate outside of the normal range.&#xD;
&#xD;
        For subjects with atopic dermatitis only:&#xD;
&#xD;
          -  Initiation of treatment of atopic dermatitis with prescription emollients during the&#xD;
             screening period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma investigational site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

